Pancreatic islet transplantation for diabetes: Successes, limitations, and challenges for the future

R. Paul Robertson

Research output: Contribution to journalArticlepeer-review

21 Scopus citations
Original languageEnglish (US)
Pages (from-to)200-205
Number of pages6
JournalMolecular Genetics and Metabolism
Issue number1-2
StatePublished - 2001

Bibliographical note

Funding Information:
Can the Edmonton results be duplicated at other centers throughout the world? The Immune Tolerance Network, funded by the Juvenile Diabetes Research Foundation and the National Institutes of Health, is currently initiating a 2-year effort involving 10 transplant centers in the United States, Canada, and Europe to answer this question. The study uses virtually the identical protocol developed by the Edmonton group. Four patients from each of the 10 centers will receive approximately 800,000 islets during two or more transplants and use the same immunosuppressive drugs used by Edmonton. By 2003 it is anticipated that all 40 patients will have been transplanted and the initial group of 12 reported by Edmonton will have been followed an averaged of 3 years. The data from this multicenter trial will answer the questions of reproducibility and longevity of success.

Copyright 2018 Elsevier B.V., All rights reserved.

Cite this